Last updated: February 25, 2026
What is NDC 00781-2352?
NDC 00781-2352 corresponds to Bupivacaine Hydrochloride Injectable Solution, a local anesthetic used for anesthesia and pain management in various surgical procedures. The drug is marketed primarily for regional anesthesia.
Market Overview
Current Market Size and Sales Trends
- The global local anesthetics market was valued at approximately USD 4.5 billion in 2022.
- The injectable segment accounted for around 75% of this market.
- Bupivacaine holds roughly 40% of the injectable local anesthetics market share domestically in the U.S. (2022 data).
- Sales volume grew at an average annual rate of 3.5% from 2018 to 2022.
Key Market Drivers
- Increase in surgical procedures requiring regional anesthesia.
- Aging population with higher chronic and surgical needs.
- Technological advancements improving drug safety and efficacy.
- Growing use in outpatient surgeries.
Competitive Landscape
| Company |
Key Products |
Market Share (approx.) |
Notable Features |
| Pfizer (marketed as Bupivacaine via Hospira) |
Bupivacaine Hydrochloride Injectable |
60-70% |
Extensive distribution network, established brand |
| Mylan (Mylan Generic Inc.) |
Bupivacaine Hydrochloride Generic |
20-30% |
Cost-effective alternative |
| Other firms |
Various biosimilar/beta products |
10-15% |
Niche regional players |
Regulatory & Patent Status
- The original patents for Bupivacaine expired in 2005.
- Several biosimilars and generics entered the market post-patent expiry.
- No recent patent exclusivity or litigations reported for this formulation.
Price Projections
Historical Price Trends
- Retail unit prices in the U.S. for Bupivacaine injectables ranged between USD 15 and USD 30 per vial (100 mg/20 mL).
- Generic versions began entering the market around 2006, causing prices to decline by approximately 25% from peak levels.
- The average wholesale price (AWP) remains relatively stable due to manufacturing costs and market demand.
Projections (2023-2028)
| Year |
Estimated Price per Vial (USD) |
Factors Influencing Price |
Confidence Level |
| 2023 |
20-25 |
Competitive generic market |
High |
| 2024 |
18-24 |
Price competition persists |
High |
| 2025 |
17-23 |
Potential for supply chain disruptions |
Moderate |
| 2026 |
16-22 |
Market stabilization, no new generics |
Moderate |
| 2027 |
15-21 |
Existing generics dominate |
Moderate |
| 2028 |
15-20 |
Industry consolidation, minimal change |
Moderate |
Factors Modifying Price Trajectory
- Increased manufacturing costs could slightly elevate prices.
- Regulatory changes favoring biosimilars may increase competition.
- Supply chain disruptions could temporarily spike costs.
- Future patent expirations or litigation may introduce new market entrants, reducing prices.
Future Market Considerations
- Emerging reformulations or delivery methods could alter demand.
- Expansion into developing markets could increase volume, moderating prices.
- Payer pressures likely to keep prices stable, favoring generics.
Key Takeaways
- The market for Bupivacaine injectable solutions remains stable with moderate growth.
- Price per vial is expected to decline gradually, driven by generic competition.
- The absence of recent patents or exclusivity supports a competitive price environment.
- Industry consolidation and new biosimilar entries could exert downward pressure.
- Supply chain risks remain a potential short-term influence on prices.
FAQs
1. Will the price of NDC 00781-2352 increase due to manufacturing costs?
It is unlikely; market competition favors stable or declining prices unless supply chain disruptions occur.
2. Are there upcoming patent expirations that could alter the market?
No recent patent expirations are reported for Bupivacaine formulations currently marketed.
3. How will biosimilar entries affect pricing?
Biosimilar entrants could increase competition, lowering prices over time.
4. What is the impact of regulations on pricing?
Regulations favoring generic and biosimilar approval may accelerate price declines.
5. Can prices vary significantly across markets?
Yes. U.S. prices tend to be higher than in emerging markets due to regulatory and market dynamics.
References
- Grand View Research. (2023). Local Anesthetics Market Size & Trends.
- IQVIA. (2022). U.S. Prescription Market Data.
- U.S. Food and Drug Administration. (2022). Approved Local Anesthetic Drugs.
- MarketWatch. (2023). Generic Drug Price Trends.
- Drugs.com. (2023). Bupivacaine Prices & News.
